At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 154 enrolled
Drug / intervention
Everolimus +1 moredrug
Likely dose
Everolimus 10 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase I/II Study of BNC105P in Combination With Everolimus or Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma Following Prior Tyrosine Kinase Inhibitors
In Brief
A Phase 2 clinical trial evaluating Everolimus and BNC105P for Renal Cell Carcinoma. Completed, enrolled 154 participants across 108 sites in 3 countries.
Detailed Summary
The purpose of this study is to determine whether BNC105P in combination with/following everolimus is effective in the treatment of progressive metastatic clear cell renal cell carcinoma following prior tyrosine kinase inhibitors.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRenal Cell Carcinoma
CountriesAustralia, Singapore, United States
CollaboratorsBionomics Limited
Timeline
Phase 2CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedDec 2009
Enrollment StartJan 2010
Primary CompletionDec 2016
TodayJul 2026
First PostedDec 17, 2009
Enrollment StartJan 1, 2010
Primary CompletionDec 1, 2016
TodayJul 2, 2026
Enrollment to primary: 6.9 yearsPosted 16.5 years ago
Interventions
Everolimusdrug
Everolimus 10 mg. Taken orally, every evening, 1 hr before or 2 hrs after meals
BNC105Pdrug
BNC105P, up to 16 mg/m\^2